Methylprednisolone (Injectable Form) + Placebo Injection
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Unruptured Intracranial Aneurysms
Conditions
Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke, Methylprednisolone, Flow Diverter
Trial Timeline
Jan 30, 2026 → Sep 1, 2027
NCT ID
NCT07353749About Methylprednisolone (Injectable Form) + Placebo Injection
Methylprednisolone (Injectable Form) + Placebo Injection is a approved stage product being developed by Brain Biotech for Unruptured Intracranial Aneurysms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07353749. Target conditions include Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07353749 | Approved | Recruiting |